Boston Scientific Corp (BSX) Stock Research Report

The tools behind a gentler kind of heart surgery

Few people know the name Boston Scientific, yet many know someone whose life it has touched. Perhaps a parent had a narrowed artery opened through a thin tube slipped in at the wrist, and went home the next day. Perhaps a friend with an irregular heartbeat was treated without anyone opening the chest.

Boston Scientific makes the instruments behind treatments like these. Its stents hold narrowed arteries open, and its pacemakers keep a faltering heart beating steadily. Its fine tubes, guided into the heart, correct an unsteady rhythm from the inside.

For several years, hospitals bought more and more of these tools, and the company grew quickly. In 2026 that growth nearly stopped, and Boston Scientific expects the pressure to last into 2027. A slowdown that long is a real test, and a return to solid growth is not yet proven.

Is the business underneath strong enough to make the wait worthwhile?

What the Company Does

Boston Scientific sells medical devices that let doctors treat illness through small openings in the body, without large cuts. Its customers are hospitals and physicians around the world, most of them in the United States. Patients rarely pay the company themselves. A hospital buys the device and uses it in a procedure, then bills Medicare, Medicaid or a private health plan.

The business has two parts of unequal size. Cardiovascular, which treats the heart and blood vessels, brings in two-thirds of sales. MedSurg covers the rest of the body, with clips for the digestive tract, lasers that break up kidney stones and implants for bladder problems.

Take a woman whose heart beats irregularly. Her hospital buys a FARAPULSE system, which uses short electrical pulses to destroy the tiny patches of tissue that upset the rhythm. Launched in 2024, the system quickly replaced older methods. It now makes up most of electrophysiology, that is, the company's treatments for heart rhythm. In 2025, electrophysiology brought in $3.3 billion, or 16.6% of sales.

A second heart device, WATCHMAN, seals a small pouch in the heart where clots tend to form. For many patients, it takes the place of blood thinners. WATCHMAN adds a further 9.8% of sales.

The company describes its aim as less-invasive treatment across many medical specialties, and it is widening that reach by buying smaller makers. Since 2024, several of these purchases have been in nerve stimulation and endoscopy. The largest, still pending, is Penumbra, which makes vacuum devices that pull clots out of blood vessels. The price is about $14.5 billion.

Electrophysiology grew this large on a product only two years old. In our reading, that suggests much of the recent boom rested on a single device.

🔒

Sign in to read the full report

Legal Notes and Methodology

Producer and publisher: Francesco Monterosso · ReasyPort
Financial information reference: 2026-03-31
Legal contact: legal@reasyport.com

Legal Disclaimer

This report is general, non-personalized research provided solely for informational and educational purposes. It is not financial or investment advice, a personalized recommendation, an offer to the public, a solicitation, an instruction to buy, sell or hold a financial instrument, or an invitation to engage in an investment activity. ReasyPort is not an authorised or regulated investment firm and does not provide a MiFID II investment service.

Methodology

This report is based on primary and public sources identified in the report, including issuer filings, annual and interim reports, regulated announcements, investor-relations materials, market data and, where relevant, institutional macroeconomic publications. Facts should be read separately from interpretations, estimates and opinions.

Text, analyses, summaries, translations and charts may be produced with the support of Artificial Intelligence and are subjected to deterministic data and consistency checks before publication. These controls reduce, but cannot eliminate, errors, omissions or incorrect interpretations. Editorial responsibility for publication remains with the producer identified above.

Estimates, updates and independence

ReasyPort View labels, fair values, forecasts, scenarios, price references and other forward-looking statements are editorial estimates or opinions, not facts or trading instructions. They depend on the assumptions, methodology, market price and information available on the stated reference date and may change without notice. The report is not monitored or updated in real time.

Any relationship, compensation, material holding or other circumstance known to ReasyPort that could reasonably impair the objectivity of a report must be disclosed with that report. Questions, corrections and potential conflicts may be reported through the legal contact shown above.

Warnings and liability

Public and primary sources, automated extraction and data providers may contain material errors, omissions, inaccuracies, restatements or delays. Accuracy, completeness and timeliness are therefore not guaranteed, and important information should be checked against the original source before it is used.

To the maximum extent permitted by applicable law, ReasyPort, the author, the publisher and the persons involved in producing the report are not liable for losses arising from decisions made solely in reliance on this report. Nothing in this notice excludes or limits any liability that cannot lawfully be excluded or limited.

Investment Risk

Any investment decision should be made independently, if appropriate with the support of a licensed financial adviser. Investments in financial instruments involve risks, including the possible partial or total loss of invested capital.

Research methodology, assumptions and disclosures Meaning of ReasyPort View

Boston Scientific Corp (BSX) - Stock report